Amgen Inc. said it will sell the cholesterol drug Repatha only at a list price 60% lower than what the company had originally charged, in a bid to make the medicine more affordable to patients and kick-start sales. Starting next year, Repatha will list for $5,850 a year for all insurers, the biotech said Thursday. Amgen began offering the treatment at the lower price last year, but still supplied Repatha in some cases at the original price of more than $14,000.

Source: Wall Street Journal October 24, 2019 19:07 UTC